# Cullinan Therapeutics

Source: https://onco.cc/companies/cullinan-therapeutics/  
OnCo record `cullinan-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cullinan develops T-cell engager antibodies, which pull a patient's T cells onto target cells, for both cancer and autoimmune disease. Its cancer lead, CLN-049, targets FLT3 on acute myeloid leukaemia cells and is entering a potentially registrational trial.

## Summary

Cullinan Therapeutics is a Cambridge, Massachusetts clinical-stage company advancing T-cell engagers (TCEs) in autoimmune disease and cancer. In oncology, CLN-049 is a FLT3xCD3 TCE for relapsed or refractory acute myeloid leukaemia; after a positive End-of-Phase 1 meeting with the FDA in July 2026 a potentially registrational phase 2 study is due to begin in the third quarter of 2026. Autoimmune programmes include CLN-978 (CD19xCD3 TCE) in lupus, rheumatoid arthritis and Sjogren's disease, and velinotamig (BCMAxCD3 TCE) in lupus, with phase 2 expansion studies planned for early 2027. The company reported $356 million in cash and investments at 30 June 2026 with runway into 2029. Nasdaq: CGEM.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Cambridge, MA
- Type: biotech
- Website: https://cullinantherapeutics.com/
- Ticker: CGEM

## Notes

- No funding round sourced. Other oncology assets (for example zipalertinib) not covered by the fetched release and therefore omitted.

## Sources

- Official website: https://cullinantherapeutics.com/
- Q2 2026 results (8-K exhibit 99.1): https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-ex99_1.htm

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD19](https://onco.cc/targets/cd19/), [CD3](https://onco.cc/targets/cd3/), [FLT3](https://onco.cc/targets/flt3/)
- trials: [A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct04036682/)

---
JSON: https://onco.cc/api/v1/entities/cullinan-therapeutics.json